Twist Bioscience Expands Infectious Disease Product Line Adding Comprehensive Viral Panel

Twist Bioscience Expands Infectious Disease Product Line Adding Comprehensive Viral Panel

— Panel Distinguishes Between More than 3,000 Different infectious Diseases —

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the availability of the Twist Comprehensive Viral Research Panel, a next-generation sequencing (NGS) panel that includes more than 3,000 viral genomes to enable identification of new and divergent viral species in a single sample. The panel will be bundled with an analysis platform from One Codex to enable an easy-to-use, complete end-to-end workflow that begins from the Twist library preparation and target enrichment panel and continues through publication-ready visualizations.

“With a renewed focus on public health and the impact of viral identification and containment, we are launching the Twist Comprehensive Viral Research Panel for researchers globally,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We do not know when the next pandemic will arrive. Through tools like this, we can identify, detect, characterize and monitor an extensive range of viral diseases to inform societal decisions.”

About the Twist Comprehensive Viral Research Panel

This innovative product contains over one million unique probes to screen for 3,153 viral human and non-human pathogens. It is designed using sequences compiled from viral genomes across RefSeq, FluDB & VIPRdb databases and represents all viral families containing at least one virus known to infect humans. The panel covers all viral genome types (ssDNA, dsDNA, ssRNA, and dsRNA) and allows for quick capture and sequencing of unknown pathogens and highly divergent viral strains. The panel detects viral co-infections and can be used to differentiate between several viruses that may cause similar symptoms. Importantly, it can be used for metagenomic surveillance applications in complex sample types including stool.

An End-to-End Solution Including One Codex Platform

The Twist Comprehensive Viral Research Panel includes analysis on the One Codex platform allowing customers to generate easy-to-share publication-ready visuals and viral identification reporting for a complete solution from panel to results. One Codex is the leading bioinformatics platform for microbial genomics, supporting taxonomic and functional analysis of next-generation sequencing (NGS) data.

The product is available for Research Use Only. View the Product Sheet for more information.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; scientific unknowns and new information relating to the SARS-CoV-2 virus; the duration, extent and impact of the COVID-19 pandemic; supply chain and other disruptions caused by the COVID-19 pandemic or otherwise; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:

Argot Partners

Maeve Conneighton

212-600-1902

[email protected]

Media Contact:

Angela Bitting

925- 202-6211

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Software Biotechnology Pharmaceutical Health Data Management Infectious Diseases Technology Genetics

MEDIA:

Logo
Logo

Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis

HAMILTON, Bermuda, Nov. 16, 2020 (GLOBE NEWSWIRE) — KiniksaPharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pathways across a spectrum of diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to vixarelimab for the treatment of pruritus associated with prurigo nodularis, a chronic inflammatory skin condition characterized by severely pruritic skin nodules. Vixarelimab is a fully-human monoclonal antibody that targets oncostatin M receptor beta (OSMRβ).

Kiniksa’s Breakthrough Therapy application was based on data from the Phase 2a clinical trial of vixarelimab in prurigo nodularis. The Phase 2a trial met its primary efficacy endpoint: there was a statistically significant reduction in weekly-average Worst-Itch Numeric Rating Scale (WI-NRS) from baseline at Week 8 in vixarelimab recipients compared to placebo recipients. Additionally, the majority of vixarelimab recipients showed a clinically meaningful greater-than-or-equal-to 4-point weekly-average WI-NRS reduction at Week 8, and a statistically significant percentage of vixarelimab recipients achieved a prurigo nodularis-investigator’s global assessment (PN-IGA) score of 0/1 at Week 8 compared to placebo recipients.

“The FDA granting Breakthrough Therapy designation to vixarelimab for the treatment of pruritus associated with prurigo nodularis is an important step forward for patients,” said Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa. “The Phase 2a study of vixarelimab in prurigo nodularis demonstrated encouraging results in both pruritus and nodule response. We believe vixarelimab has the potential to positively impact the lives of those suffering from prurigo nodularis, a devastating disease for which there are no FDA-approved therapies.”

Kiniksa expects to initiate a Phase 2b clinical trial of vixarelimab in prurigo nodularis, evaluating a range of once-monthly dose regimens, by the end of the year.

About
Breakthrough Therapy
Designation

The FDA defines Breakthrough Therapy designation as a process designed to expedite the development and review of drug candidates that are intended to treat a serious condition, and preliminary clinical evidence indicates that the drug candidate may demonstrate substantial improvement over available therapies on a clinically significant endpoint.

About
Vixarelimab
 Phase 2a Trial in Prurigo 
Nodularis

The Phase 2a trial was a randomized, double-blind, placebo-controlled study designed to investigate the efficacy, safety, tolerability, and pharmacokinetics of vixarelimab in reducing pruritus in subjects with prurigo nodularis. The trial enrolled patients with moderate-to-severe prurigo nodularis experiencing moderate-to-severe pruritus (WI-NRS ≥ 7 at the screening visit and a mean weekly WI-NRS of ≥ 5 for each of the two consecutive weeks immediately prior to randomization). Patients were required to stop antihistamines and topical treatments, including corticosteroids, for at least two weeks prior to dosing. Prurigo nodularis treatments, other than study drug, were not allowed except for rescue. For more information, refer to ClinicalTrials.gov Identifier: NCT03816891.

About
Vixarelimab

Vixarelimab is an investigational fully-human monoclonal antibody that targets OSMRβ, which mediates signaling of interleukin-31 (IL-31) and oncostatin M (OSM), two key cytokines implicated in pruritus, inflammation and fibrosis. Kiniksa believes vixarelimab to be the only monoclonal antibody in development that targets both pathways simultaneously. Kiniksa’s lead indication for vixarelimab is prurigo nodularis, a chronic inflammatory skin condition characterized by severely pruritic skin nodules. The FDA granted Breakthrough Therapy designation to vixarelimab for the treatment of pruritus associated with prurigo nodularis in 2020.

About Kiniksa

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These pipeline assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: our beliefs about research, pre-clinical and clinical trial data demonstrating encouraging results; our beliefs about the potential to positively impact the lives of patients with prurigo nodularis and the importance for such patients of vixarelimab having been granted Breakthrough Therapy designation for the treatment of prurigo nodularis; planned clinical trials and timing thereof, including a potential dose-ranging Phase 2b clinical trial of vixarelimab in prurigo nodularis; and our beliefs about the mechanisms of action of our product candidates and potential impact of their approach.

These forward-looking statements are based on management’s current plans, estimates or expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including without limitation, the following: delays or difficulty in enrollment of patients in, and activation or continuation of sites for, our clinical trials; potential complications in coordinating among requirements, regulations and guidelines of regulatory authorities across a number of jurisdictions for our global clinical trials; potential amendments to our clinical trial protocols initiated by us or required by regulatory authorities; delays or difficulty in completing our clinical trials, including as a result of the COVID-19 pandemic; potential for low accrual of events in our clinical trials; potential undesirable side effects caused by our product candidates; our potential inability to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities or otherwise producing negative, inconclusive or commercially uncompetitive results; potential for applicable regulatory authorities to not accept our BLA or sBLA filings or to delay or deny approval of any of our product candidates or to require additional trials to support any such approval; potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials conducted by us or third parties, including from investigator initiated studies; impact of additional data from us or other companies; potential inability to replicate in later clinical trials positive results from earlier pre-clinical and clinical trials or studies of our product candidates potential in subsequent clinical trials conducted by us or third parties, including investigator-initiated studies; drug substance and/or drug product shortages; our reliance on third parties as the sole source of supply of the drug substance and drug products used in our product candidates; our reliance on third parties to conduct our research, pre-clinical studies, clinical trials, and other trials for our product candidates; substantial existing or new competition; impact of the COVID-19 pandemic, and measures taken in response to the pandemic, on our business and operations as well as the business and operations of our manufacturers, CROs upon whom we rely to conduct our clinical trials, and other third parties with whom we conduct business or otherwise engage, including the FDA and other regulatory authorities; changes in our operating plan and funding requirements; and our ability to attract and retain qualified personnel.

These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 5, 2020 and our other reports subsequently filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s plans, estimates, or expectations as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. 


Every Second


Counts!™

Kiniksa Investor and Media Contact

Mark Ragosa
(781) 430-8289
[email protected]



HealthWarehouse.com Reports Results for Third Quarter 2020

HealthWarehouse.com Reports Results for Third Quarter 2020

Elects New Board Member; Receives BBB Torch Award for Marketplace Ethics

CINCINNATI–(BUSINESS WIRE)–
HealthWarehouse.com, Inc. (OTC: HEWA) announced today that its net sales for the third quarter of 2020 were $4,004,462. It reported a loss from operations of $15,693 for the quarter but positive cash flow, as reflected by its internal measure of Adjusted EBITDA as defined below, which was $188,631 in the third quarter.

HealthWarehouse.com is an online mail-order pharmacy authorized to sell and deliver prescription medications to all 50 states and is one of the first accredited digital pharmacies approved by the National Association of Boards of Pharmacy (NABP).

Shareholders of the Company elected a new independent director, Sara Mannix, to the Board of Directors at their virtual annual meeting held on October 7, 2020. Mannix is CEO of Mannix Marketing, a digital marketing and search engine optimization company. In addition, the Shareholders reelected the three existing Board Members and the Series B preferred director and approved a number of proposals including the increase in the number of authorized common shares, a 50-to-1 reverse split of the common shares, and increased the awards available under the 2014 equity incentive plan.

Joseph Peters, President and CEO of HealthWarehouse.com, said, “We are happy to have Sara on the Board, and look forward to her valuable contributions as we evaluate and implement an strategy to position the Company for future sales growth amidst the changing landscape in marketing and advertising during the pandemic.”

The Company also announced an agreement with the holders of its Series C Preferred stock, who retracted a previous notice of redemption and agreed to terms to convert their positions to common shares. The new agreement will enable the Company to continue the improvement to its balance sheet and capital structure.

HealthWarehouse.com was recently named a 2020 Torch Award winner by the Better Business Bureau. The award honors companies for the strength of their commitment to exceptional ethical business practices.

“Our mission is to provide affordable healthcare through honesty and compassion. Receiving this award is an honor, and a testament to the drive and dedication of our incredible team at HealthWarehouse.com,” Peters added.

Healthwarehouse.com is an essential business and continues to operate during the pandemic. Over sixty percent of its 110 employees work remotely; a dedicated fulfillment team continues to operate on-site.

“We continue to adjust operations and be as agile as possible in our procedures in the ever-changing landscape the pandemic has brought us,” Peters added. “The HealthWarehouse.com team has done an incredible job in remaining dedicated to our mission. Everyone on-site and off-site has risen to the challenge and continues to provide the excellent pharmacy services that our patients have come to know and love.”

2020 Overview:

Net Sales: Total net sales for the three and nine months ended September 30, 2020 were $4,004,462 and $13,089,244, respectively, a decrease of $31,014 (1%) and an increase of $1,204,080 (10%), respectively, over the same periods in 2019. Prescription sales including fulfillment were $3,223,364 and $10,018,051, respectively, for the three and nine months ended September 30, 2020; they represent increases of $3,961 and $641,769 (7%), respectively, over the same periods in 2019. Over-the-counter sales were $689,564 and $2,727,382, respectively, for the three and nine months ended September 30, 2020, a decrease of $46,468 (6%) and an increase of $450,268 (20%), respectively, over the same periods in 2019. The year-to-date revenue increase was due to increased order volumes resulting from higher levels of website traffic and conversions, increased third-party fulfillment revenues, and customer retention efforts.

Gross Profit: Gross profit for the three and nine months ended September 30, 2020, was $2,761,159 and $8,633,926, respectively, resulting in increases of $115,401 and $796,156, respectively, compared with results for the same periods of 2019. The increases were the result of higher sales volume and purchasing initiatives with our vendors.

Operating Expenses: Selling, general and administrative expenses were $2,731,321 and $8,651,345, respectively, for the three and nine months ended September 30, 2020, and increases of $142,027 (5%) and $926,567 (12%), respectively, compared to the same periods of 2019. The increases were primarily from higher variable expenses, including advertising, marketing, shipping, supplies and payment processing expenses, as well as salary expense related to engineering staff expansion and hero bonuses paid to all employees.

Net Income and Adjusted EBITDA: The Company reported net losses of $15,693 and $177,420, respectively, for the three and nine months ended September 30, 2020, compared with net losses of $4,830 and $83,201, respectively, for the same periods in 2019.

Earnings before interest, taxes, depreciation and amortization (“EBITDA”), as adjusted for stock-based compensation and certain non-recurring charges (“Adjusted EBITDA”), were $188,631 for the three months and $450,680 for the nine months ended June 30, 2020. That compares with Adjusted EBITDA of $199,500 and $563,032, respectively, for the three and nine months ended June 30, 2019. EBITDA and Adjusted EBITDA are non-GAAP financial measures. Definitions of these non-GAAP terms and a reconciliation to GAAP measures are provided below.

HEALTHWAREHOUSE.COM, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

For the Three Months Ended

 

For the Nine Months Ended

September 30,

 

September 30,

2020

 

2019

 

2020

 

2019

 
Net sales

$

4,004,462

 

$

4,035,476

 

$

13,089,244

 

$

11,885,164

 

 
Cost of sales

 

1,243,303

 

 

1,389,718

 

 

4,455,318

 

 

4,047,393

 

 
Gross profit

 

2,761,159

 

 

2,645,758

 

 

8,633,926

 

 

7,837,771

 

 
Selling, general and administrative expenses

 

2,731,321

 

 

2,589,294

 

 

8,651,345

 

 

7,724,778

 

 
Net income (loss) from operations

 

29,838

 

 

56,464

 

 

(17,419

)

 

112,993

 

 
Interest expense

 

(45,530

)

 

(61,294

)

 

(160,001

)

 

(196,194

)

 

 

 

 

 

 

 

 

Net loss

 

(15,692

)

 

(4,830

)

 

(177,420

)

 

(83,201

)

 
Preferred stock:
Series B convertible contractual dividends

 

(85,559

)

 

(85,559

)

 

(256,675

)

 

(256,675

)

 
Net loss attributable to common stockholders

$

(101,251

)

$

(90,389

)

$

(434,095

)

$

(339,876

)

 
Per share data:
Net loss – basic and diluted

$

(0.00

)

$

(0.00

)

$

(0.00

)

$

(0.00

)

Series B convertible contractual dividends

$

(0.00

)

$

(0.00

)

$

(0.01

)

$

(0.01

)

 
Net loss attributable to common stockholders – basic and diluted $ (0.00 ) $ (0.00 ) $ (0.01 ) $ (0.01 )
 
Weighted average common shares outstanding – Basic and diluted

 

50,851,971

 

 

50,041,900

 

 

50,761,665

 

 

49,797,154

 

 

Use of Non-GAAP Financial Measures

HealthWarehouse.com, Inc. (the “Company”) prepares its consolidated financial statements in accordance with the United States generally accepted accounting principles (“GAAP”). In addition to disclosing financial results prepared in accordance with GAAP, the Company discloses information regarding EBITDA and Adjusted EBITDA, which are commonly used. In addition to adjusting net loss to exclude interest, taxes, depreciation and amortization (“EBITDA”), Adjusted EBITDA also excludes stock-based compensation, and certain nonrecurring charges. EBITDA and Adjusted EBITDA are not measures of performance defined in accordance with GAAP. However, Adjusted EBITDA is used internally in planning and evaluating the Company’s performance. Accordingly, management believes that disclosure of this metric offers lenders and other shareholders an additional view of the Company’s operations that, when coupled with GAAP results, provides a more complete understanding of the Company’s financial results.

Adjusted EBITDA should not be considered as an alternative to net loss or to net cash used in operating activities as a measure of operating results or of liquidity. It may not be comparable to similarly titled measures used by other companies, and it excludes financial information that some may consider important in evaluating the Company’s performance.

Reconciliation of Net Income (Loss) (GAAP) to Adjusted EBITDA (Non-GAAP)

 

Three Months Ended

 

 

Nine Months Ended

September 30,

 

 

September 30,

(Unaudited)

2020

 

2019

 

 

2020

 

2019

 
Net loss

$

(15,693

)

$

(4,830

)

$

(177,420

)

$

(83,201

)

Interest expense

 

45,530

 

 

61,294

 

 

160,001

 

 

196,194

 

Depreciation and amortization

 

33,319

 

 

42,800

 

 

100,282

 

 

128,337

 

EBITDA (non-GAAP)

 

63,156

 

 

99,264

 

 

82,863

 

 

241,330

 

Adjustments to EBITDA:
Stock-based compensation

 

125,475

 

 

100,236

 

 

367,817

 

 

321,702

 

 
Adjusted EBITDA

$

188,631

 

$

199,500

 

$

450,680

 

$

563,032

 

 

About HealthWarehouse.com

HealthWarehouse.com, Inc. (OTC Pink: HEWA) is America’s Leading Online Pharmacy and a pioneer in affordable healthcare. Based in Florence, Kentucky, the Company’s services are available nationwide, shipping FDA approved prescription medication and over-the-counter products direct to patients’ doors. As one of the first National Association of Boards of Pharmacy (“NABP”) Accredited Digital Pharmacies, HealthWarehouse.com services the mission of providing affordable healthcare and incredible patient services to help Americans in all 50 states. Learn more at www.HealthWarehouse.com.

Forward-Looking Statements

This announcement and the information incorporated by reference herein contain “forward­looking statements” as defined in federal securities laws, including but not limited to Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, which statements are based on our current expectations, estimates, forecasts and projections. Statements that are not historical facts, including statements about the beliefs, expectations and future plans and strategies of the Company, are forward-looking statements. Actual results may differ materially from those expressed in forward looking statements or in management’s expectations. Important factors which could cause or contribute to actual results being materially and adversely different from those described or implied by forward looking statements include, among others, risks related to competition, management of growth, access to sufficient capital to fund our business and our growth, new products, services and technologies, potential fluctuations in operating results, international expansion, outcomes of legal proceedings and claims, fulfillment center optimization, seasonality, commercial agreements, acquisitions and strategic transactions, foreign exchange rates, system interruption, cyber-attacks, access to sufficient inventory, government regulation and taxation, payments, and fraud. More information about factors that potentially could affect HealthWarehouse.com’s financial results is included in HealthWarehouse.com’s audited Annual Reports and Quarterly Reports available at otcmarkets.com for periods since 2016, and its filings for prior periods with the Securities and Exchange Commission.

Joseph Peters, (800) 748-7001

KEYWORDS: United States North America Ohio

INDUSTRY KEYWORDS: General Health Online Retail Health Retail Pharmaceutical

MEDIA:

Brighthouse Financial Announces Preferred Stock Dividends and Related Depositary Share Distributions

Brighthouse Financial Announces Preferred Stock Dividends and Related Depositary Share Distributions

CHARLOTTE, N.C.–(BUSINESS WIRE)–
Brighthouse Financial, Inc. (“Brighthouse Financial” or the “company”) (Nasdaq: BHF) announced today that on December 28, 2020, holders of record as of December 10, 2020 (the “Record Date”) of (i) its depositary shares (the “Series A Depositary Shares” (Nasdaq: BHFAP)), each representing a 1/1,000th interest in a share of its 6.600% Non-Cumulative Preferred Stock, Series A (the “Series A Preferred Stock”) and (ii) its depositary shares (the “Series B Depositary Shares” (Nasdaq: BHFAO)), each representing a 1/1,000th interest in a share of its 6.750% Non-Cumulative Preferred Stock, Series B (the “Series B Preferred Stock”), will receive the following quarterly distributions, as applicable:

  • a quarterly distribution in an amount of $0.4125 per Series A Depositary Share, resulting from the company’s declaration of a quarterly dividend on the Series A Preferred Stock, which underlies the Series A Depositary Shares; and
  • a quarterly distribution in an amount of $0.421875 per Series B Depositary Share, resulting from the company’s declaration of a quarterly dividend on the Series B Preferred Stock, which underlies the Series B Depositary Shares.

On December 28, 2020, (i) the Series A Preferred Stock dividend will be paid, in an amount of $412.50 per share, to the depositary for the Series A Preferred Stock and (ii) the Series B Preferred Stock dividend will be paid, in an amount of $421.875 per share, to the depositary for the Series B Preferred Stock. The depositary will, in turn, distribute such dividends to the holders of record of the Series A Depositary Shares and the Series B Depositary Shares, as applicable, as of the Record Date.

Note Regarding Forward-Looking Statements

This news release and other oral or written statements that we make from time to time may contain information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties. We have tried, wherever possible, to identify such statements using words such as “anticipate,” “estimate,” “expect,” “project,” “may,” “will,” “could,” “intend,” “goal,” “target,” “guidance,” “forecast,” “preliminary,” “objective,” “continue,” “aim,” “plan,” “believe” and other words and terms of similar meaning, or that are tied to future periods, in connection with a discussion of future operating or financial performance. In particular, these include, without limitation, statements relating to future actions, prospective services or products, financial projections, future performance or results of current and anticipated services or products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, as well as trends in operating and financial results.

Any or all forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining the actual future results of Brighthouse Financial. These statements are based on current expectations and the current economic environment and involve a number of risks and uncertainties that are difficult to predict. These statements are not guarantees of future performance. Actual results could differ materially from those expressed or implied in the forward-looking statements due to a variety of known and unknown risks, uncertainties and other factors. Risks, uncertainties, and other factors that might cause such differences include the risks, uncertainties and other factors identified in Brighthouse Financial’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, particularly in the sections entitled “Risk Factors” and “Quantitative and Qualitative Disclosure About Market Risk,” as well as in Brighthouse Financial’s other subsequent filings with the U.S. Securities and Exchange Commission. Further, any forward-looking statement speaks only as of the date on which it is made, and Brighthouse Financial does not undertake any obligation to update or revise any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as otherwise may be required by law.

About Brighthouse Financial, Inc.

Brighthouse Financial, Inc. (Brighthouse Financial) (Nasdaq: BHF) is on a mission to help people achieve financial security. As one of the largest providers of annuities and life insurance in the U.S.,1 we specialize in products designed to help people protect what they’ve earned and ensure it lasts. Learn more at brighthousefinancial.com.

1 Ranked by 2019 admitted assets. Best’s Review®: Top 200 U.S. Life/Health Insurers. A.M. Best, 2020.

FOR INVESTORS

David Rosenbaum

(980) 949-3326

[email protected]

FOR MEDIA

Deon Roberts

(980) 949-3071

[email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Professional Services Insurance Finance

MEDIA:

Logo
Logo

Korn Ferry to Report Quarterly Earnings via Live Webcast on November 23, 2020

Korn Ferry to Report Quarterly Earnings via Live Webcast on November 23, 2020

LOS ANGELES–(BUSINESS WIRE)–
Korn Ferry (NYSE:KFY) today announced that the firm will release financial results for the fiscal year 2021 second quarter (ended October 31, 2020) on Monday, November 23, 2020.

A press release will be issued before the market opens on Monday, November 23, 2020, followed by a live webcast at 12:00 p.m. EST. The webcast will be hosted by Gary Burnison, Chief Executive Officer and Robert Rozek, Chief Financial Officer.

What:

Korn Ferry to Report Q2 FY2021 Earnings

Investor Live Webcast

 

Who:

Gary Burnison, Chief Executive Officer

Robert Rozek, Chief Financial Officer

Gregg Kvochak, Senior Vice President, Investor Relations

 

When:

12:00 p.m. EST, Monday, November 23, 2020

 

Where:

Live audio webcast and accompanying slides will be available at the following site: https://ir.kornferry.com/events-and-presentations

About Korn Ferry

Korn Ferry is a global organizational consulting firm. We work with our clients to design optimal organization structures, roles, and responsibilities. We help them hire the right people and advise them on how to reward and motivate their workforce while developing professionals as they navigate and advance their careers.

Investor Relations: Gregg Kvochak, (310) 556-8550

For Media: Dan Gugler, (310) 226-2645

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Consulting Professional Services Finance

MEDIA:

Logo
Logo

Newsday Names Zebra Technologies to Long Island Top Workplaces 2020

Newsday Names Zebra Technologies to Long Island Top Workplaces 2020

Zebra ranked #5 among top 10 large employers on Long Island

HOLTSVILLE, N.Y.–(BUSINESS WIRE)–Zebra Technologies Corporation (NASDAQ: ZBRA), an innovator at the front line of business with solutions and partners that deliver a performance edge, today announced it has been awarded a Top Workplaces 2020 honor by Newsday for the third consecutive year. The list of awarded employers is based solely on employee feedback gathered by Energage, LLC. Its anonymous survey measures multiple aspects of workplace culture, including alignment, execution, and connection, just to name a few.

With more than 50 years of technology expertise and leadership, Zebra has grown to be one of the largest employers of high technology professionals on Long Island. Zebra continues to drive technical innovation and customer value and has been investing approximately 10% of its $4.5 billion annual revenue in research and development.

“Zebra takes pride in creating a culture of innovation, inclusion, collaboration and respect that enables our employees to bring their best selves to work each day,” said Bill Burns, Chief Product & Solutions Officer, Zebra Technologies. “On behalf of our Long Island-based community of builders, doers and problem solvers, we are honored to receive this recognition.”

This year, Zebra was also awarded a special accolade for communication. Surveyed employees said open and transparent communication from management keeps them well informed and enables them to plan work and family life.

Zebra remains an active participant in the Long Island community. Employees are provided with up to four days of volunteer paid time off per year to support their efforts and they have used these to volunteer with organizations such as Island Harvest, FIRST® Inspires, Long Island Cares, Habitat for Humanity of Suffolk County and the New York Blood Center. Earlier this year, Zebra donated healthcare supplies to a New York hospital to aid with COVID-19 pandemic response efforts.

“In times of great change, it is more important than ever to maintain a connection among employees,” said Eric Rubino, Energage CEO. “When you give your employees a voice, you come together to navigate challenges and shape your path forward based on real-time insights into what works best for your organization. The Top Workplaces program can be that positive outcome your company can rally around in the coming months to celebrate leadership and the importance of maintaining an employee-focused culture, even during challenging times.”

The full list of Newsday’s Top Workplaces 2020 is available at https://projects.newsday.com/business/long-island-top-work-places/.

KEY TAKEAWAYS

  • For the third consecutive year, Zebra Technologies has been named to Newsday’s Long Island Top Workplaces.
  • Newsday Long Island Top Workplaces 2020 is an annual ranking of the top employers on Long Island. The rankings are based solely on employee feedback.
  • Zebra invests approximately 10% of its $4.5 billion annual revenue in research and development to continue advancing technical innovation and customer value.
  • Zebra is committed to “doing well by doing good” in the communities where we live and work. New York employees are provided four days of volunteer paid time off to support charitable organizations.

ABOUT ZEBRATECHNOLOGIES

Zebra (NASDAQ: ZBRA) empowers the front line in retail/ecommerce, manufacturing, transportation and logistics, healthcare, public sector and other industries to achieve a performance edge. With more than 10,000 partners across 100 countries, Zebra delivers industry-tailored, end-to-end solutions to enable every asset and worker to be visible, connected and fully optimized. The company’s market-leading solutions elevate the shopping experience, track and manage inventory as well as improve supply chain efficiency and patient care. In 2020, Zebra made Forbes Global 2000 list for the second consecutive year and was listed among Fast Company’s Best Companies for Innovators. For more information, visit www.zebra.com orsign up for news alerts.Participate in Zebra’s Your Edge blog, follow the company on LinkedIn, Twitter and Facebook, and check out our Story Hub: Zebra Perspectives.

ABOUT ENERGAGE

Energage offers a fully unified SaaS platform, plus support and professional services, to help organizations recruit and retain the right talent. As a B-Corporation founding member, Energage has committed itself to the purpose of making the world a better place to work together. Based on 14 years of culture research, the engine behind 51 Top Workplaces programs across the country, and data gathered from over 20 million employees at 60,000 organizations, Energage has isolated the 15 drivers of engaged cultures that are critical to the success of any business, and developed the tools and expertise to help organizations measure, shape and showcase their unique culture to achieve a sustainable competitive advantage. For more information, please visit energage.com. Follow us on Twitter @teamenergage and Facebook and LinkedIn @energage.

Media Contact:

Melissa Wagner

Zebra Technologies

Phone: +1-312-971-8540

[email protected]

Industry Analyst Contact:

Kasia Fahmy

Zebra Technologies

+1-224-306-8654

[email protected]

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Security Technology Mobile/Wireless Software Internet Hardware

MEDIA:

Logo
Logo

Synovus Opens New Branch in Atlanta’s Upper Westside

Synovus Opens New Branch in Atlanta’s Upper Westside

COLUMBUS, Ga.–(BUSINESS WIRE)–
Synovus Bank has opened a new banking center in Atlanta’s Upper Westside. The Marietta Boulevard branch is located at 2211 Marietta Boulevard, across the street from the new Westside Village @ Moores Mill development.

Led by Retail Market Manager Bob Millar, the branch provides a full range of personal and business banking products, home mortgage products, and private wealth management services. The 2,500 square-foot branch includes a 24-hour walk-up vestibule ATM, drive-up ATM, private banking offices, and a conference room. Lobby and drive-thru hours are Monday through Thursday 9 a.m. – 5 p.m. ET, Friday 9 a.m. – 6 p.m. ET, and Saturday 9 a.m. – 12 p.m. ET.

With the Marietta Boulevard branch, Synovus operates 46 branches in metro Atlanta and three within the City of Atlanta.

Synovus Bank, a Georgia-chartered, FDIC-insured bank, provides commercial and retail banking, investment, and mortgage services together with its affiliates through 289 branches in Georgia, Alabama, South Carolina, Florida, and Tennessee. Synovus Bank has been recognized as one of the country’s “Most Reputable Banks” by American Banker and the Reputation Institute. Synovus Bank is on the web at synovus.com, and on Twitter, Facebook, LinkedIn, and Instagram. Equal Housing Lender.

Lee Underwood

Media Relations

(706) 644-0528

KEYWORDS: United States North America Georgia

INDUSTRY KEYWORDS: Banking Other Professional Services Professional Services Finance

MEDIA:

New Special Edition WD_BLACK Drives From Western Digital Enable Gamers to Heed the Call of Duty

New Special Edition WD_BLACK Drives From Western Digital Enable Gamers to Heed the Call of Duty

Call of Duty®: Black Ops Cold War Gets Next-Level Performance with WD_BLACK Collector’s Edition Storage Products

SAN JOSE, Calif.–(BUSINESS WIRE)–
Western Digital (NASDAQ: WDC) is working with Call of Duty to reimagine three high-performance products from the WD_BLACK™ portfolio, bringing gamers three special edition storage drives that encapsulate the Call of Duty: Black Ops Cold War look and feel with the added bonus of in-game Call of Duty points.1 These three products include the WD_BLACK P10 Game Drive, WD_BLACK P50 Game Drive SSD and the recently announced WD_BLACK SN850 NVMe™ SSD featuring PCIe® Gen4 technology.*

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201116005222/en/

Call of Duty®: Black Ops Cold War gets next-level performance with three WD_BLACK™ collector’s edition storage drives. (Photo: Business Wire)

Call of Duty®: Black Ops Cold War gets next-level performance with three WD_BLACK™ collector’s edition storage drives. (Photo: Business Wire)

“We are excited that this collaboration with Call of Duty gives us the opportunity to bring these limited edition specially designed drives to their passionate fans,” said Jim Welsh, Senior Vice President of Consumer Solutions at Western Digital. “We know gamers are exceptionally serious when it comes to their gameplay, so we created optimized storage solutions that enable them to keep up with the immersive Call of Duty experience.”

“As we’re delivering the next generation of Black Ops to the gaming community, we’re committed to ensuring our fans have the absolute best gaming experience,” said Ander Nickell, Global Director of Brand Partnerships and Integrated Marketing at Activision. “Western Digital’s WD_BLACK brand is made for gamers, and together we believe our fans will be as thrilled as we are about these drives.”

The upcoming themed special edition drives include:

WD_BLACK Call of Duty: Black Ops Cold War Special Edition P10 Game Drive: The WD_BLACK P10 Game Drive is built specifically for gamers looking to expand the potential of their compatible console2 or PC, by saving their game library in an on-the-go form factor. Free with purchase, gamers will receive a voucher for 1,100 Call of Duty points that can be redeemed for items within the game1. This special edition drive will be available in a 2TB** model and retails for $109.99 MSRP. For more information on this product, visit the Western Digital store. It is expected to be available for purchase at select Western Digital retailers and e-tailers early December 2020.

WD_BLACK Call of Duty: Black Ops Cold War Special Edition P50 Game Drive SSD: The WD_BLACK P50 Game Drive SSD provides PC and compatible consoles2 with insanely high read speeds so players spend less time waiting to get back in the game and more time actually playing. Gamers who purchase this drive will also receive a voucher for 2,400 Call of Duty points that can be redeemed for items within the game1. This special edition drive will be available in a 1TB** model and retails for $249.99 MSRP. For more information on this product, visit the Western Digital store. It is expected to be available for purchase at select Western Digital retailers and e-tailers in December 2020.

WD_BLACK Call of Duty: Black Ops Cold War Special Edition SN850 NVMe SSD (1TB**): This high-performance future-ready product reduces game load times and transfers files faster than the previous generation. Powered by next-gen PCIe Gen4 technology,* the WD_BLACK SN850 NVMe SSD delivers smoother loading of applications, allowing users to boot up quickly. Free with purchase is 2,400 Call of Duty points that can be redeemed for items within the game1. This special edition drive will be available in a 1TB** non-heatsink model for $239.99 MSRP. For more information on this product, visit the Western Digital store. It is expected to be available for purchase at select Western Digital retailers and e-tailers in December 2020.

To learn more about these products and the WD_BLACK brand, visit www.WDBLACK.com.

About Western Digital

Western Digital creates environments for data to thrive. As a leader in data infrastructure, the company is driving the innovation needed to help customers capture, preserve, access and transform an ever-increasing diversity of data. Everywhere data lives, from advanced data centers to mobile sensors to personal devices, our industry-leading solutions deliver the possibilities of data. Our data-centric solutions consist of the Western Digital®, G-Technology™, SanDisk®, and WD® brands.

*The WD_BLACK SN850 is not intended for NAS or server environments.

**As used for storage capacity, 1TB = 1 trillion bytes. Actual user capacity may be less depending on operating environment.

1 Call of Duty: Black Ops Cold War game sold separately. Internet connection and Activision account required. Offer limited to one per qualifying product purchase. Limit 5 Call of Duty Points (CP) redemptions (limit only applies to this Western Digital promotion). CP will be usable once enabled in Call of Duty: Black Ops Cold War. Offer must be redeemed by date shown on the sticker on the front of your packaging, while CP supplies last. Western Digital reserves the right to change or discontinue this offer at any time without notice.

2 Compatible with PlayStation™ 4 and PlayStation 5 (for PS4™ games only) or Xbox One™ and Xbox™ Series X|S (for Xbox One™ games only) consoles.

© 2020 Western Digital Corporation or its affiliates. All rights reserved.

Western Digital, the Western Digital logo, G-Technology, SanDisk, WD, WD_BLACK and the WD_BLACK logo are registered trademarks or trademarks of Western Digital Corporation or its affiliates in the U.S. and/or other countries. NVMe™ is a trademark of NVM Express, Inc. PCIe® is a registered trademark and/or service mark of PCI-SIG in the United States and/or other countries. Thunderbolt and the Thunderbolt logo are trademarks of Intel Corporation or its subsidiaries in the U.S. and/or other countries. Windows is a trademark or registered trademark of Microsoft Corporation in the United States and/or other countries. CALL OF DUTY and CALL OF DUTY BLACK OPS are trademarks of Activision Publishing, Inc. All other marks are the property of their respective owners.

Product specifications subject to change without notice. Pictures shown may vary from actual products. Not all products are available in all regions of the world.

T. Peter Andrew

Western Digital Corporation

Investor Relations

+1 (949) 672-9655

[email protected]

Stacy DeVera

Western Digital Corporation

Public Relations

+1 (949) 672-9764

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Data Management Women Consumer Electronics Technology Men Online Mobile Entertainment Specialty Mobile/Wireless Consumer Retail Electronic Games Teens Entertainment General Entertainment Audio/Video Software Networks Internet Hardware Online Retail

MEDIA:

Photo
Photo
Call of Duty®: Black Ops Cold War gets next-level performance with three WD_BLACK™ collector’s edition storage drives. (Photo: Business Wire)
Photo
Photo
WD_BLACK™ Call of Duty®: Black Ops Cold War Special Edition P50 Game Drive SSD (Photo: Business Wire)
Photo
Photo
WD_BLACK™ Call of Duty®: Black Ops Cold War Special Edition SN850 NVMe SSD (Photo: Business Wire)
Photo
Photo
WD_BLACK™ Call of Duty®: Black Ops Cold War Special Edition P10 Game Drive (Photo: Business Wire)
Logo
Logo

Syros Pharmaceuticals to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

Syros Pharmaceuticals to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference. Management will also be available for one-on-one meetings on Tuesday, December 1, 2020.

The fireside chat will be available for on-demand viewing on the Investors & Media Section of the Syros website, www.syros.com, beginning Monday, November 23, 2020 at 10:00 a.m. ET and will remain available for approximately 30 days.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust pipeline, including SY-1425, a first-in-class oral selective RARα agonist in a Phase 2 trial in a genomically defined subset of acute myeloid leukemia patients, and SY-5609, a highly selective and potent oral CDK7 inhibitor in a Phase 1 trial in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

Media Contact:

Naomi Aoki

Syros Pharmaceuticals

617-283-4298

[email protected]

Investor Contact:

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Biotechnology Health Genetics Pharmaceutical Oncology

MEDIA:

Logo
Logo

HPE (Aruba) Positioned as a Leader in Gartner Magic Quadrant for Wired and WLAN Access Infrastructure, Scores Highest in All Use Cases in Critical Capabilities Report

HPE (Aruba) Positioned as a Leader in Gartner Magic Quadrant for Wired and WLAN Access Infrastructure, Scores Highest in All Use Cases in Critical Capabilities Report

Positioned as Leader for Fifteenth1 Year Running and Furthest in Vision of All Vendors

SANTA CLARA, Calif.–(BUSINESS WIRE)–
Aruba, a Hewlett Packard Enterprise company (NYSE: HPE), today announced that for the fifteenth year, HPE (Aruba) has been positioned in the Leaders quadrant in Gartner Inc.’s latest “Magic Quadrant for Wired and Wireless LAN Access Infrastructure,” and is positioned furthest to the right in Vision, as compared to all vendors. In addition, in the companion “Critical Capabilities for Wired and Wireless LAN Access Infrastructure” report, Aruba has received the highest score in all six use cases – the second time it has scored highest across all use cases.

Read complimentary copies of the Magic Quadrant and Critical Capabilities reports here:

2020 Magic Quadrant for Wired and Wireless LAN Infrastructure

2020 Critical Capabilities for Wired and Wireless LAN Infrastructure

Read Aruba’s blog about this year’s reports here:

Aruba and the Gartner Wired and Wireless LAN Infrastructure Magic Quadrant

Gartner evaluates vendors included in the Magic Quadrant based on two primary criteria: completeness of vision and ability to execute. HPE (Aruba) was positioned the furthest in vision of all vendors in the quadrant, which Aruba believes recognizes the company’s continued innovation and ability to anticipate and address customer challenges.

In addition, in the companion piece to the Magic Quadrant, the Gartner Critical Capabilities for Wired and Wireless LAN Access Infrastructure, Gartner evaluated vendor effectiveness in addressing an organization’s needs in six key use cases: Unified Wired and WLAN Access, WLAN-only Refresh/New Build, Wired-only Refresh/New build, Remote Branch Office with Corporate HQ, Performance Stringent Applications, and Hands-off NetOps. Aruba received the highest scores in all six of these use cases.

“Our ‘Customer First, Customer Last’ culture drives our commitment and focus across the entire Aruba organization from building our products and delivering our services, to helping our customers and partners in the field and supporting them on the back-end,” said Michael Dickman, senior vice president of Product Management at Aruba, a Hewlett Packard Enterprise company. “The continued recognition by Gartner of HPE (Aruba) is gratifying and we couldn’t be prouder of our clear market leadership via Aruba ESP (Edge Services Platform). The networking landscape may have changed over the past 15 years with different vendors coming and going but Aruba’s commitment to customer-driven innovation has kept us on the forefront at every step, becoming the Edge authority that the market turns to time and again. We are grateful to our customers and partners for their continued trust.”

In addition to the 2020 Magic Quadrant for Wired and Wireless LAN Access Infrastructure and Critical Capabilities reports, HPE (Aruba) has also been recognized by Gartner for other aspects of its industry-leading portfolio. In September 2020, just two years after launching its SD-Branch solution, Aruba was recognized as a Visionary in the Gartner Magic Quadrant for WAN Edge Infrastructure, and Silver Peak, recently acquired by HPE (Aruba) was positioned as a Leader for the third consecutive year. HPE (Aruba) was also positioned as a Visionary in the 2020 Magic Quadrant for Data Center and Cloud Networking.

Additional Resources

Gartner Magic Quadrant for Wired and Wireless LAN Access Infrastructure, Bill Menezes, Tim Zimmerman, Christian Canales, Mike Toussaint, 5 November 2020

Gartner Critical Capabilities for Wired and Wireless LAN Infrastructure, Christian Canales, Tim Zimmerman, Bill Menezes, Mike Toussaint, 11 November 2020

1 Aruba’s 15 years of placement includes HPE (Aruba) in the Magic Quadrant for Wired & Wireless LAN Access Infrastructure from 2015-2020 (6 years), Aruba Networks in the same Magic Quadrant from 2012-2014 (3 years) and in the Magic Quadrant for Wireless LAN Access Infrastructure from 2006-2011 (6 years).

Gartner disclaimer

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Aruba, a Hewlett Packard Enterprise company

Aruba, a Hewlett Packard Enterprise company, is the global leader in secure, intelligent edge-to-cloud networking solutions that use AI to automate the network, while harnessing data to drive powerful business outcomes. With Aruba ESP (Edge Services Platform) and as-a-service options, Aruba takes a cloud-native approach to helping customers meet their connectivity, security, and financial requirements across campus, branch, data center, and remote worker environments, covering all aspects of wired, wireless LAN, and wide area networking (WAN).

To learn more, visit Aruba at http://www.arubanetworks.com. For real-time news updates follow Aruba on Twitter and Facebook, and for the latest technical discussions on mobility and Aruba products, visit Airheads Social at http://community.arubanetworks.com/.

Kathleen Keith

Aruba, a Hewlett Packard Enterprise company

+1 707-529-4507

[email protected]

Jennifer Miu

Aruba, a Hewlett Packard Enterprise company

+1 650-236-9532

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Data Management Technology Mobile/Wireless Software Networks Internet Hardware

MEDIA:

Logo
Logo